Ascendis Pharma’s SKYTROFA Approved by FDA for Adult Growth Hormone Deficiency
Ascendis Pharma A/S announced that the FDA has approved SKYTROFA (lonapegsomatropin-tcgd) for the treatment of adult growth hormone deficiency (GHD). Already approved for pediatric GHD since 2021, SKYTROFA is a once-weekly prodrug of somatropin designed to provide sustained release of unmodified human growth hormone, offering a less burdensome alternative to daily injections.
“This important milestone is the first of many planned label expansions supporting our goal to become the leading endocrinology rare disease company,” said Jan Mikkelsen, President and CEO of Ascendis Pharma. “W...